Literature DB >> 6317543

Mechanisms for eosinophil degranulation; release of the eosinophil cationic protein.

I Winqvist, T Olofsson, I Olsson.   

Abstract

Mechanisms for degranulation in human eosinophils were evaluated. Release of eosinophil cationic protein (ECP), a unique eosinophil granule constituent, was measured upon exposure of purified eosinophils to a large surface consisting of Sephadex beads coated with serum, which leads to complement activation. Extracellular release of approximately 15% of the cellular ECP occurred both with eosinophils from patients with eosinophilia and normal people. Almost all eosinophils isolated from patients with eosinophilia and normal people adhered to serum-treated Sephadex. The data suggest that interaction through C3 receptors is a prerequisite for ECP release from eosinophils when exposed to serum-treated Sephadex. Both cytochalasin B, cytochalasin D and hydrocortisone reduced the release of ECP. Neither the cytochalasins nor hydrocortisone inhibited the adherence of eosinophils to the Sephadex beads. Thus the inhibitory effect of these agents on ECP release is a direct effect on the degranulation process. ECF-A, histamine and colchicine did not affect the release mechanism. No direct relationship was found between degranulation and oxidative burst inasmuch as some soluble mediators induced a high respiratory burst without a concomitant ECP release. Our data suggest that mechanisms for degranulation are not fully identical in eosinophils and neutrophils.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6317543      PMCID: PMC1454395     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Human eosinophil adherence to serum-treated sepharose: granule-associated enzyme release and requirement for activation of the alternative complement pathway.

Authors:  D D Metcalfe; J E Gadek; G D Raphael; M M Frank; A P Kaplan; M Kaliner
Journal:  J Immunol       Date:  1977-11       Impact factor: 5.422

3.  Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils.

Authors:  G J Gleich; D A Loegering; K G Mann; J E Maldonado
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

4.  Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase.

Authors:  S I Wasserman; E J Goetzl; K F Austen
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

5.  Arginine-rich cationic proteins of human eosinophil granules: comparison of the constituents of eosinophilic and neutrophilic leukocytes.

Authors:  I Olsson; P Venge; J K Spitznagel; R I Lehrer
Journal:  Lab Invest       Date:  1977-05       Impact factor: 5.662

6.  Histaminase release from human eosinophils.

Authors:  R S Zeiger; H R Colten
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

7.  Radioimmunoassay of human eosinophil cationic protein.

Authors:  P Venge; L E Roxin; I Olsson
Journal:  Br J Haematol       Date:  1977-11       Impact factor: 6.998

8.  Action of cytochalasin D on cells of established lines. II. Cortex and microfilaments.

Authors:  A F Miranda; G C Godman; S W Tanenbaum
Journal:  J Cell Biol       Date:  1974-08       Impact factor: 10.539

9.  Identification of a major basic protein in guinea pig eosinophil granules.

Authors:  G J Gleich; D A Loegering; J E Maldonado
Journal:  J Exp Med       Date:  1973-06-01       Impact factor: 14.307

10.  Physiochemical and biological properties of the major basic protein from guinea pig eosinophil granules.

Authors:  G J Gleich; D A Loegering; F Kueppers; S P Bajaj; K G Mann
Journal:  J Exp Med       Date:  1974-08-01       Impact factor: 14.307

View more
  11 in total

1.  Eosinophil granules function extracellularly as receptor-mediated secretory organelles.

Authors:  Josiane S Neves; Sandra A C Perez; Lisa A Spencer; Rossana C N Melo; Lauren Reynolds; Ionita Ghiran; Salahaddin Mahmudi-Azer; Solomon O Odemuyiwa; Ann M Dvorak; Redwan Moqbel; Peter F Weller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-18       Impact factor: 11.205

Review 2.  What is the role of the eosinophil?

Authors:  P Venge
Journal:  Thorax       Date:  1990-03       Impact factor: 9.139

3.  Replenishment of RANTES mRNA expression in activated eosinophils from atopic asthmatics.

Authors:  J R Velazquez; P Lacy; R Moqbel
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

4.  PI3-kinase regulates eosinophil and neutrophil degranulation in patients with allergic rhinitis and allergic asthma irrespective of allergen challenge model.

Authors:  Mary Kämpe; Maria Lampinen; Ingrid Stolt; Christer Janson; Gunnemar Stålenheim; Marie Carlson
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

5.  Release of eosinophil cationic protein (ECP) in anaphylactoid anaesthetic reactions in vivo and in vitro.

Authors:  E S Assem
Journal:  Agents Actions       Date:  1994-06

6.  Monoclonal antibodies to human eosinophil plasma membrane antigens enhance the secretion of eosinophil cationic protein.

Authors:  P C Tai; M Capron; D M Bakes; J Barkans; C J Spry
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

Review 7.  Eosinophilic disorders affecting the myocardium and endocardium: a review.

Authors:  C J Spry; M Take; P C Tai
Journal:  Heart Vessels Suppl       Date:  1985

8.  Patients with allergic rhinitis and allergic asthma share the same pattern of eosinophil and neutrophil degranulation after allergen challenge.

Authors:  Mary Kämpe; Ingrid Stolt; Maria Lampinen; Christer Janson; Gunnemar Stålenheim; Marie Carlson
Journal:  Clin Mol Allergy       Date:  2011-01-21

Review 9.  Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity.

Authors:  Francis Davoine; Paige Lacy
Journal:  Front Immunol       Date:  2014-11-10       Impact factor: 7.561

10.  Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium.

Authors:  A Slungaard; G M Vercellotti; G Walker; R D Nelson; H S Jacob
Journal:  J Exp Med       Date:  1990-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.